EUVIMEDEUVIMED entdecken
LeserbriefKommentar

Comment on: In vitro activity of cefiderocol against MBL-producing Gram-negative bacteria collected in North America and Europe in five consecutive annual multinational SIDERO-WT surveillance studies (2014–2019)

Sathyavani Subbarao iD, Sara E Boyd, Marina Basarab, Peter Riley

Journal of Antimicrobial Chemotherapy · 2024

DOI: 10.1093/jac/dkae110 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Sathyavani Subbarao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Infection Care Group, St George's Hospital NHS Foundation Trust, London, SW17 0QT, UK. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Gram-Negative Bacteria, Microbial Sensitivity Tests, Cefiderocol. Die Arbeit nennt 6 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We read with interest the work of Miki Takemura and colleagues who observed global patterns of cefiderocol resistance amongst isolates producing MBLs collected in North America and Europe in multinational SIDERO-WT surveillance studies.1 The SIDERO-WT surveillance studies conducted between 2014 and 2019 included approximately 46 000 Gram-negative clinical isolates. It was found that 200/902 (22.0%) of meropenem-resistant Enterobacterales isolates produced MBL enzymes, 67.5% of which had a cefiderocol MIC value of less than the 2 mg/L breakpoint set by EUCAST. Carbapenemase-producing Gram-negative bacteria pose a significant threat to health as there are limited therapeutic options,2 especially for isolates that produce MBL enzymes. However, cefiderocol may retain activity against Enterobacterales that produce MBL enzymes. The gold standard method for antimicrobial susceptibility testing (AST) of cefiderocol is broth microdilution (BMD) using iron-depleted cation-adjusted Mueller–Hinton broth,3 but this is not readily in available in most clinical laboratories. Disc diffusion (DD) is relatively easier, lower in cost and a well-standardized method for AST in clinical laboratories and, for cefiderocol, does not require iron-depleted media. Interpretive criteria and breakpoints for BMD and DD have been defined by EUCAST. However, breakpoints for DD have required adjustment, with the latest guidance update as of 1 January 2024 showing a change from 22 mm [area of technical uncertainty (ATU) 18–22 mm] to 23 mm (ATU 21–23 mm) for Enterobacterales. The MIC breakpoints have remained the same in the latest edition.4 St George’s Hospital (SGH) in London is a UK tertiary level teaching hospital served by South West London Pathology (SWLP), which operates a large onsite regional clinical diagnostic microbiology laboratory. Similar to other comparable laboratories across England, our method for examining cefiderocol susceptibility is the EUCAST DD method. We have also observed an increase in detection of Enterobacterales producing carbapenemases, notably NDM enzymes, including conflict-associated infections.5 Review of our laboratory data for all patients admitted to SGH, who had a confirmed Gram-negative isolate producing NDM enzymes identified either by molecular testing (Xpert Carba-R, Cepheid) or by immunochromatography (NG-Test Carba-5, NG Biotech) from 2020 until 2023, identified 67 isolates: Thirty (44.8%) of these isolates, comprising 25 (83.3%) Enterobacterales, two Pseudomonas aeruginosa, and three Acinetobacter baumanii (Table 1) underwent cefiderocol DD susceptibility testing. Among the Enterobacterales, interpretation of DD zone size using EUCAST v13.1 saw 19/25 (76%) reported as resistant, 6/25 (24%) as susceptible, with 10/25 (40%) reported within the ATU (Table 1). Applying the EUCAST update from v14.0 resulted in only one less isolate being categorized in the ATU (Table 1). Comparative reported cefiderocol susceptibility for Gram-negative organisms producing NDM enzymes according to EUCAST guidance V13.1 and V14.0a aThe number of isolates for each species reported as susceptible or resistant. The numbers in brackets represent how many of those results also fell within the respective ATUs. Comparative reported cefiderocol susceptibility for Gram-negative organisms producing NDM enzymes according to EUCAST guidance V13.1 and V14.0a aThe number of isolates for each species reported as susceptible or resistant. The numbers in brackets represent how many of those results also fell within the respective ATUs. Without access to readily available corroborative MICs for these isolates, these results demonstrate the ongoing difficulty of interpreting cefiderocol susceptibility by DD alone. Although there has been a reduction of the ATU in updated guidelines, we now see a reduction in isolates reported as susceptible without much change in the number that remain in the ATU. Going forward this means more accurately identifying when cefiderocol has a low probability of therapeutic success. However, we highlight here ongoing limitations of interpreting disc zone size measurements when they lie within the ATU, and reliable MICs are not readily available, potentially leading to unnecessary avoidance in use of a valuable reserve antimicrobial agent. The current advice for isolates falling within the ATU is that they should be retested by BMD or by similar methodology, reported as resistant or not reported at all,6 but without the emphasis on retesting and the facilities to enable this we potentially risk over-reporting resistance, in spite of the refined ATU. Implementation of DD as the first-line method for cefiderocol susceptibility testing presents technical uncertainty that may affect accurate interpretation of susceptibility for this agent. Further correlation of isolates reported within the new ATU, both by BMD and associated with clinical outcomes if cefiderocol is used, is important in better understanding and optimizing its utility in managing these difficult-to-treat infections. We thank all the staff at South West London Pathology and Dr Scott J.C. Pallet for reviewing the manuscript. This study did not receive any external funding and data were generated as part of the routine work of SWLP. The authors declare the following competing interests: S.E.B. holds the Young Scientist Seat for the British Society for Antimicrobial Chemotherapy Antimicrobial Susceptibility Testing Committee. S.E.B. has consulted for bioMérieux and Sumitovant, received speaker fees from Shionogi and the UK Clinical Pharmacy Association, and was supported by a research grant obtained through a Medical Research Council (MRC)-awarded UK Research and Innovation Fellowship within the North West England MRC Scheme in Clinical Pharmacology with support from Roche Pharma (2017–21). All other authors have no conflicts of interest to declare.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsGram-Negative BacteriaMicrobial Sensitivity TestsCefiderocolbeta-LactamasesCephalosporinsEuropeHumansNorth AmericaGram-Negative Bacterial InfectionsEpidemiological Monitoring

Substanzen

Anti-Bacterial AgentsCefiderocolbeta-LactamasesCephalosporins

Autor:innen und Institutionen

  • Infection Care Group, St George's Hospital NHS Foundation Trust, London, SW17 0QT, UK.
  • NIHR Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, London, UK.
  • Antimicrobial Pharmacodynamics and Therapeutics, Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK.

ORCID-Profile: Sathyavani Subbarao

Zitieren

APA

Subbarao, S., Boyd, S. E., Basarab, M., & Riley, P. (2024). Comment on: In vitro activity of cefiderocol against MBL-producing Gram-negative bacteria collected in North America and Europe in five consecutive annual multinational SIDERO-WT surveillance studies (2014–2019). Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae110

Vancouver

Subbarao S, Boyd SE, Basarab M, Riley P. Comment on: In vitro activity of cefiderocol against MBL-producing Gram-negative bacteria collected in North America and Europe in five consecutive annual multinational SIDERO-WT surveillance studies (2014–2019). Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae110

BibTeX
@article{Subbarao2024,
  author = {Subbarao, Sathyavani and Boyd, Sara E and Basarab, Marina and Riley, Peter},
  title = {Comment on: In vitro activity of cefiderocol against MBL-producing Gram-negative bacteria collected in North America and Europe in five consecutive annual multinational SIDERO-WT surveillance studies (2014–2019)},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2024},
  doi = {10.1093/jac/dkae110}
}
Kostenlos starten →